Post-Market Evidence Generation: Bridging PV and HTA for Long-Term Access
Post-market evidence generation is becoming a strategic priority for life sciences companies. After a drug or medical device gains regulatory approval, the focus quickly shifts to long-term access, pricing, and continued patient benefit. This shift requires new, real-world evidence to validate both product safety and health system value. At the intersection of pharmacovigilance (PV) and […]
Post-Market Evidence Generation: Bridging PV and HTA for Long-Term Access Read More »